Extract
Sarcoidosis is complex and highly variable, with protean clinical manifestations and a wide array of consequences for patients. The course is likewise unpredictable, leading to the moniker “sarcoidoses” to connote that sarcoidosis may be a syndrome rather than a single disease [1]. Delineating distinct subgroups, “phenotypes”, has been an attempt to simplify prediction about individual patients and to homogenise groups for research purposes. Sarcoidosis phenotypes have been used most often to predict prognosis or to cluster patients with similar outcomes [2–5]. But phenotyping could also be used primarily to stratify patients by clinical features such as extent of organ involvement, or by perceived severity [6, 7].
Abstract
Novel approaches to cluster sarcoidosis by organ clusters may yield new clinical and pathophysiologic insights http://ow.ly/uCVG30hMsro
Footnotes
Conflict of interest: D.A. Culver has received non-financial support from Araim and Gilead, and grants and personal fees from Mallinckrodt and Foundation for Sarcoidosis Research, outside the submitted work. R.P. Baughman has received grants from Gilead, Bayer, National Institutes of Health, Genentech, Mallinckrodt and Foundation for Sarcoidosis Research, personal fees for consultancy from Genentech and Mallinckrodt, and fees for speaking from Mallinckrodt, outside the submitted work.
- Received January 9, 2018.
- Accepted January 11, 2018.
- Copyright ©ERS 2018